The ongoing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic
necessitates the fast development of vaccines to meet a worldwide need. mRNA-based …

Abstract mRNA technologies have recently proven clinical efficacy against coronavirus
disease 2019 and are among the most promising technologies to address the current …

There is an urgent need for vaccines to counter the COVID-19 pandemic due to infections
with severe acute respiratory syndrome coronavirus (SARS-CoV-2). Evidence from …

Abstract The CVnCoV (CureVac) mRNA vaccine for severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) was recently evaluated in a phase 2b/3 efficacy trial in …

Messenger RNA (mRNA) vaccine technology has shown its power in preventing the
ongoing COVID-19 pandemic. Two mRNA vaccines targeting the full-length S protein of …

At the forefront of biopharmaceutical industry, the messenger RNA (mRNA) technology
offers a flexible and scalable platform to address the urgent need for world-wide …

More than a year after emergence of the SARS-CoV-2 pandemic, multiple first-generation
vaccines are approved and available for vaccination. Still, many challenges remain. The …

Although COVID-19 vaccines have been developed, multiple pathogenic coronavirus
species exist, urging on development of multispecies coronavirus vaccines. Here we …

The emergence of highly transmissible severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) variants of concern (VOCs) that are resistant to the current COVID-19 …

SARS-CoV-2 infection has emerged as a serious global pandemic. Because of the high
transmissibility of the virus and the high rate of morbidity and mortality associated with …